Thalidomide is a potent immunomodulator and a TNF-α inhibitor, originally used for treatment of multiple myeloma and erythema nodosum leprosum (Jung et al., 2019) and evaluated for repurposing across numerous neurological disorders due to its multipotent pleiotropic characteristics. This evidence concerns the gene TNF and plasma cell myeloma.